Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.Reuters Health Information http://ift.tt/2qiZFOy
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου